Search research articles
Contact Us
Filters
Showing results (1-10 of 52) with videos related to
Page
of 6
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 5, 2021
Comorbidities and behavioral issues
Dragana Bugarski-Kirola, Ronald N Marcus
The Journal of Clinical Psychiatry
|
April 11, 2025
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Paul P Yeung, Alan Breier, Haiyuan Zhu, et al.
Psychopharmacology
|
October 24, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
Wlodzimierz K Chrzanowski, Ronald N Marcus, Anne Torbeyns, et al.
Current Medical Research and Opinion
|
May 1, 2010
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study
Eduard Vieta, Randall Owen, Christine Baudelet, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
April 22, 2008
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study
David Taylor, Linda Hanssens, Jean-Yves Loze, et al.
BMC Psychiatry
|
December 24, 2008
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
Linda Hanssens, Gilbert L'Italien, Jean-Yves Loze, et al.
Journal of the American Medical Directors Association
|
December 30, 2008
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia
Stephen A Rappaport, Ronald N Marcus, George Manos, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence
Raymond F Anton, Henry Kranzler, Christopher Breder, et al.
The Journal of Clinical Psychiatry
|
October 27, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo
Gilbert J L'Italien, Daniel E Casey, Hong J Kan, et al.
Journal of Psychiatric Research
|
July 17, 2007
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
Joseph P McEvoy, David G Daniel, William H Carson, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 52) with videos related to
Sort By:
Page
of 6
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
April 5, 2021
Comorbidities and behavioral issues
Dragana Bugarski-Kirola, Ronald N Marcus
The Journal of Clinical Psychiatry
|
April 11, 2025
Xanomeline and Trospium Chloride for the Treatment of Agitation Associated With Schizophrenia: PANSS-Excited Component Results From 3 Randomized, Double-Blind, Placebo-Controlled EMERGENT Trials
Paul P Yeung, Alan Breier, Haiyuan Zhu, et al.
Psychopharmacology
|
October 24, 2006
Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine
Wlodzimierz K Chrzanowski, Ronald N Marcus, Anne Torbeyns, et al.
Current Medical Research and Opinion
|
May 1, 2010
Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study
Eduard Vieta, Randall Owen, Christine Baudelet, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists
|
April 22, 2008
Preference of medicine and patient-reported quality of life in community-treated schizophrenic patients receiving aripiprazole vs standard of care: results from the STAR study
David Taylor, Linda Hanssens, Jean-Yves Loze, et al.
BMC Psychiatry
|
December 24, 2008
The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913)
Linda Hanssens, Gilbert L'Italien, Jean-Yves Loze, et al.
Journal of the American Medical Directors Association
|
December 30, 2008
A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia
Stephen A Rappaport, Ronald N Marcus, George Manos, et al.
Journal of Clinical Psychopharmacology
|
January 22, 2008
A randomized, multicenter, double-blind, placebo-controlled study of the efficacy and safety of aripiprazole for the treatment of alcohol dependence
Raymond F Anton, Henry Kranzler, Christopher Breder, et al.
The Journal of Clinical Psychiatry
|
October 27, 2007
Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo
Gilbert J L'Italien, Daniel E Casey, Hong J Kan, et al.
Journal of Psychiatric Research
|
July 17, 2007
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia
Joseph P McEvoy, David G Daniel, William H Carson, et al.
Page
of 6